Business Wire

MA-DEME-OFFSHORE-US

5.11.2021 07:02:12 CET | Business Wire | Press release

Share
DEME Offshore Lands Dominion Energy Group’s +$1.1 Billion Balance of Plant (BoP) Project for Construction of Coastal Virginia Offshore Wind Farm (CVOW)

DEME Offshore US LLC (“DEME Offshore” or “the Company”), the world’s leading offshore wind farm contractor, today announced that it has secured a +$1.1 Billion Balance of Plant (BoP) contract for the construction of the Coastal Virginia Offshore Wind (CVOW) project in a Consortium with Prysmian. The contract, with a total value amounting to +$1.9 Billion, has been awarded by Dominion Energy Virginia, a subsidiary of Dominion Energy Inc., to a consortium made up of DEME Group and Prysmian.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104006432/en/

The agreement is the largest offshore wind installation contract ever awarded in the U.S. Upon expected completion in 2026, the CVOW will be the largest wind farm in the U.S., and one of the largest in the world.

The CVOW project will play a crucial role in helping the Commonwealth of Virginia meet its goal of becoming carbon neutral by 2045. The project is located at approximately 27 miles (43 km) off the coast of Virginia Beach, VA, US. The 2.6GW offshore wind farm will be capable of supplying clean energy to as many as 660,000 households, while reducing carbon emissions by over 2 million tons per year.

DEME Offshore’s CVOW BoP contract includes the transport and installation of 176 monopile transition piece foundations, three offshore substations, scour protection and the supply and installation of export and inter-array submarine cable systems. DEME Offshore will oversee the complete offshore installation works for the foundations, substations, infield cables, as well as part of the export cables. For the fulfilment of the project, DEME Offshore entered in a consortium with Prysmian, the world leader in underwater energy cable systems.

“DEME Offshore brings valuable industry knowledge and years of experience to our Coastal Virginia Offshore Wind project ,” says Joshua Bennett, Dominion Energy vice president of offshore wind . “We look forward to working with DEME Offshore to advance offshore wind off the coast of Virginia as we lead the Commonwealth’s clean-energy transition .”

Luc Vandenbulcke, CEO, DEME Group comments: “We are extremely proud to be playing such a significant role in this dynamic and growing U.S. market and seeing our efforts bring clean energy to American households. Following the award of the Vineyard offshore wind project installation works for foundations, substation and wind turbines and South Fork cable installation works, this partnership with Dominion Energy is an endorsement of our expertise and track record in enabling the energy transition process in the U.S. This contract further reaffirms DEME’s position as the pre-eminent contractor in the offshore wind installation industry both in the U.S. and globally.”

“We are grateful for Dominion Energy for the opportunity to launch this consortium. By working closely with our partners at Prysmian Powerlink, we will jointly support the project during the design and preparation phase with our joint expertise, and ultimately deliver on the promise of offshore wind power to the benefit of Virginia residents, businesses, and families,” said Jan Klaassen, Director, DEME Offshore US LLC.

Sid Florey, President, DEME Offshore US , commented: “This significant contract will allow us to further build out our US footprint, working with key partners and the local supply chain to grow jobs. We are pleased to continue supporting the growth of the U.S. offshore wind industry and demonstrating DEME’s commitment to this growing market.”

DEME Group has spent many years building up its presence in the U.S. market and established DEME Offshore US LLC in Boston in 2019. Today’s CVOW announcement is a fast follow on from earlier contract awards for Vineyard Wind 1 off the coast of Massachusetts, the first utility-scale offshore wind project in the U.S., and the South Fork offshore wind farm off the coast of Long Island. Upon expected completion in 2023, these projects will generate clean, renewable, affordable energy for over 400,000 homes and businesses in Massachusetts and over 70,000 homes on Long Island, while reducing carbon emissions by 1.6 million tons per year and 300,000 tons per year, respectively.

About DEME Offshore US LLC

DEME Offshore US LLC is a US company based in Boston, Massachusetts. DEME Offshore US LLC will source the installation vessel and experts from DEME Offshore, a member of the DEME Group. DEME Group, a world leader in the specialized fields of dredging, solutions for the offshore energy industry, infra marine and environmental works. The company can build on more than 140 years of know-how and is a front runner in innovation and new technologies. DEME’s vision is to work towards a sustainable future by offering solutions for global challenges: a rising sea level, a growing population, reduction of CO2 emissions, polluted rivers and soils and the scarcity of natural resources. DEME can rely on 5,200 highly skilled professionals and a modern fleet of over 100 vessels.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release

Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release

Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release

Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye